 | ||
   | ||
Email
Glossary |
|
Heb B Surfance Antigen/LFT Mar 15, 2010 My younger brother was recently asked by his doctor to have Hepatitis tests; and the following results came back: Hep B. Surface Antigen (Reactive) 6250 Cut off Rate 1.0 Hep C. Antibody (Non Reactive) 0.091 S. Total Bilirubin 0.5 mg/dl S. Direct Bilirubin 0.1 mg/dl S. Indirect Bilirubin 0.4 mg/dl Gamma GT 21 IUL SGPT (ALT) 16 IUL Alkaline Phosphatase 56 IUL Kindly advise about the interpretation of these results and what/how we can get his treatment going. Thankyou for your kindness in advance, may Allah Bless you for your wonderful work. Best Regards |
||||||||
 |
||||||||||
|
||||||||||
 |
| Response from Dr. McGovern
 Thank you for your kind words. It is not clear whether your brother needs treatment. He has normal liver function tests and his hepatitis B surface antigen indicates chronic infection - however, he could have active or inactive infection. The difference is determined by the presence of viremia (eg, virus in the blood). The test that distinguishes the two is a HBV DNA test. This can be an expensive test. In the meantime, he should have LFTs done about every 3 to 6 months to be certain they continue to be normal. That would be very reassuring... My best wishes for your brother's health. | ||||||||
 Get Email Notifications When This Forum Updates or Subscribe With RSS
|
||||||||||
|
||||||||||
Q&A TERMS OF USE
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.
Review our complete terms of use and copyright notice.
